Creative Biolabs Expands Lipid-Based Formulation Services for Diverse Therapeutics

Creative Biolabs has announced the expansion of its lipid-based drug delivery services. These services are designed to support researchers involved in developing various therapeutics, including mRNA, siRNA drugs, protein biologics, vaccines, and gene delivery systems. The expanded platform integrates custom liposome and lipid nanoparticle (LNP) formulation capabilities with particle characterization, stability evaluation, and scalable manufacturing support.

The expansion of lipid-based drug delivery services addresses a persistent challenge in the development of next-generation therapeutics. Many advanced biologics, including mRNA, siRNA, and gene therapies, encounter significant barriers to effective delivery, such as payload instability, enzymatic degradation, and inefficient cellular uptake. Platforms that offer comprehensive formulation design, particle characterization, and stability evaluation are crucial for overcoming these obstacles. By providing support from early discovery through to preclinical development, these services aim to enable researchers to protect payloads, achieve controlled release, and optimize particle performance, thereby facilitating the progression of complex therapies through the research pipeline.

The availability of both custom liposome and lipid nanoparticle (LNP) formulation services broadens the utility for a diverse range of therapeutic modalities. LNPs are particularly relevant for nucleic acid delivery, while liposomes offer solutions for proteins, peptides, and small molecules, as well as controlled-release applications. Offering capabilities like ionizable lipid screening, microfluidic formulation, and scalable manufacturing support is important for ensuring consistency and reproducibility in drug product development. Such comprehensive support systems can help bridge the gap between initial scientific discoveries and their translation into viable preclinical candidates, potentially accelerating the development of new treatments across various disease areas.